RESEARCH TRIANGLE PARK – Gene editing startup Locus Biosciences is another step closer to actualizing its biotherapeutics against bacterial diseases after landing $35 million in additional capital.
MORRISVILLE – Gene editing startup Locus Biosciences has landed another $7 million in new cash, adding to a year that has brought commitments of nearly $100 million. According to a securities filing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results